Search
Bendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.
PF-06273340
go.drugbank.com/drugs/DB12269Investigationalof Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)). … Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
Molindone
go.drugbank.com/drugs/DB01618ApprovedIt has only low to moderate affinity for cholinergic and alpha-adrenergic receptors.
Azelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigational[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Products: AZEP EYE DROPS 0.05% w/v, OPTIHIST EYE DROPS 0.05% w/vEmpasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]
Diphenylguanidine
go.drugbank.com/drugs/DB14191ApprovedSensitivity to diphenylguanidine may be identified with a clinical patch test.
Brentuximab
go.drugbank.com/drugs/DB05471Investigationalto on normal cells. … We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). … substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat
Loxapine
go.drugbank.com/drugs/DB00408ApprovedInvestigationalAn antipsychotic agent used in schizophrenia. [PubChem]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome